Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(28.6%)

Phase 4

2(28.6%)

Phase 2

2(28.6%)

N/A

1(14.3%)

7Total

Phase 1(2)

Phase 4(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04763759Phase 1Completed

Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

Role: collaborator

NCT01389024Phase 2Completed

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

Role: collaborator

NCT01806077Phase 1Completed

Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors

Role: collaborator

NCT01323764Phase 4Completed

ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients

Role: collaborator

NCT02450175Not ApplicableUnknown

Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls

Role: lead

NCT02188550Phase 2Unknown

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Role: lead

NCT00848133Phase 4Completed

A Comparison of Subvastus and Midvastus Approaches in Minimally-Invasive Total Knee Arthroplasty

Role: lead

All 7 trials loaded